ASCO
<ѻý>ASCO: Platinum-Taxane Regimen No Benefit for Thymoma or Thymic Carcinoma
ѻý>
CHICAGO -- For treatment-naive advanced thymoma or thymic carcinoma, carboplatin (Paraplatin) and paclitaxel (Taxol) failed to achieve response rates approaching those reported in published trials of athracycline-based regimens.
Jun 05, 2008
<ѻý>ASCO: In Endometrial Cancer, Less GI Toxicity with Brachytherapy than External-Beamѻý>
CHICAGO --Vaginal brachytherapy is as effective in preventing a recurrence of endometrial cancer after surgery in women with high-intermediate risk disease as external-beam pelvic radiotherapy but with less gastrointestinal toxicity, Dutch researchers reported here.
Jun 01, 2008
<ѻý>ASCO: High Dose Pemetrexed (Alimta) Fails to Increase Survival in NSCLCѻý>
CHICAGO -- Increasing the dose of pemetrexed (Alimta) to 900 mg/m2 did not improve outcome for patients with advanced non-small cell lung cancer (NSCLC), but did slightly increase toxicity, researchers found.
Jun 08, 2007